Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTX NASDAQ:JANX NASDAQ:KRRO NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$15.39+2.2%$14.82$10.60▼$38.12$1.59B0.28899,259 shs1.07 million shsJANXJanux Therapeutics$26.91+0.6%$24.24$21.73▼$71.71$1.61B2.82936,620 shs594,728 shsKRROKorro Bio$46.35+10.0%$33.37$10.29▼$85.00$395.83M2.89293,547 shs216,659 shsVCELVericel$36.02+2.0%$33.71$29.24▼$63.00$1.78B1.39684,448 shs411,112 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics0.00%-0.33%+5.61%+12.47%-57.66%JANXJanux Therapeutics0.00%+0.94%+14.12%+2.61%-46.51%KRROKorro Bio0.00%-1.91%+16.92%+215.97%-47.34%VCELVericel0.00%+10.89%+11.49%-0.39%-15.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$15.39+2.2%$14.82$10.60▼$38.12$1.59B0.28899,259 shs1.07 million shsJANXJanux Therapeutics$26.91+0.6%$24.24$21.73▼$71.71$1.61B2.82936,620 shs594,728 shsKRROKorro Bio$46.35+10.0%$33.37$10.29▼$85.00$395.83M2.89293,547 shs216,659 shsVCELVericel$36.02+2.0%$33.71$29.24▼$63.00$1.78B1.39684,448 shs411,112 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics0.00%-0.33%+5.61%+12.47%-57.66%JANXJanux Therapeutics0.00%+0.94%+14.12%+2.61%-46.51%KRROKorro Bio0.00%-1.91%+16.92%+215.97%-47.34%VCELVericel0.00%+10.89%+11.49%-0.39%-15.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.69Moderate Buy$38.83152.33% UpsideJANXJanux Therapeutics 2.94Moderate Buy$78.31191.00% UpsideKRROKorro Bio 3.00Buy$86.8387.34% UpsideVCELVericel 2.71Moderate Buy$58.4062.13% UpsideCurrent Analyst Ratings BreakdownLatest KRRO, VCEL, JANX, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $41.0010/14/2025KRROKorro BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025VCELVericelZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025EWTXEdgewise TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025JANXJanux TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VCELVericelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025EWTXEdgewise TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025JANXJanux TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025KRROKorro BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025VCELVericelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/25/2025EWTXEdgewise TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$20.00(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/AJANXJanux Therapeutics$10.59M152.69N/AN/A$19.49 per share1.38KRROKorro Bio$2.27M191.73N/AN/A$17.12 per share2.71VCELVericel$237.22M7.66$0.32 per share113.03$5.92 per share6.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)KRROKorro Bio-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)VCELVericel$10.36M$0.12300.1981.86N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest KRRO, VCEL, JANX, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025KRROKorro Bio-$2.61N/AN/AN/A$0.41 millionN/A11/6/2025Q3 2025EWTXEdgewise Therapeutics-$0.40N/AN/AN/AN/AN/A11/6/2025Q3 2025VCELVericel-$0.02N/AN/AN/A$64.57 millionN/A11/5/2025Q3 2025JANXJanux Therapeutics-$0.60N/AN/AN/A$3.07 millionN/A8/12/2025Q2 2025KRROKorro Bio-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 million8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A28.8728.87JANXJanux TherapeuticsN/A47.0347.03KRROKorro BioN/A5.985.98VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AJANXJanux Therapeutics75.39%KRROKorro Bio13.18%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics23.20%JANXJanux Therapeutics29.40%KRROKorro Bio4.60%VCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableJANXJanux Therapeutics3060.09 million42.43 millionOptionableKRROKorro Bio709.39 million8.96 millionNo DataVCELVericel30050.46 million46.83 millionOptionableKRRO, VCEL, JANX, and EWTX HeadlinesRecent News About These CompaniesConestoga Capital Advisors LLC Buys 401,990 Shares of Vericel Corporation $VCELOctober 20 at 3:33 AM | marketbeat.comWilliam Blair Investment Management LLC Sells 123,021 Shares of Vericel Corporation $VCELOctober 19 at 5:20 AM | marketbeat.comVericel (NASDAQ:VCEL) Trading Up 5.6% - Here's What HappenedOctober 17 at 3:11 PM | marketbeat.comVericel (NASDAQ:VCEL) Upgraded by Zacks Research to "Strong-Buy" RatingOctober 16, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Acquires 610,045 Shares of Vericel Corporation $VCELOctober 16, 2025 | marketbeat.comAberdeen Group plc Buys Shares of 209,217 Vericel Corporation $VCELOctober 16, 2025 | marketbeat.comVericel price target lowered to $41 from $46 at TruistOctober 16, 2025 | msn.comTruist Securities Maintains Vericel (VCEL) Buy RecommendationOctober 16, 2025 | msn.comLeerink Partnrs Has Pessimistic View of Vericel Q4 EarningsOctober 15, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 15, 2025 | americanbankingnews.comVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 10, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Receives "Sell (D+)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comVericel Corporation $VCEL Shares Purchased by PFG Investments LLCOctober 4, 2025 | marketbeat.comCanaccord Genuity Keeps Their Buy Rating on Vericel (VCEL)September 26, 2025 | theglobeandmail.comVericel Corporation $VCEL Shares Acquired by Congress Asset Management Co.September 26, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Hits New 12-Month Low - Time to Sell?September 25, 2025 | marketbeat.comKopp Family Office LLC Sells 8,554 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.comVoya Investment Management LLC Purchases 10,048 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.com18,200 Shares in Vericel Corporation $VCEL Purchased by Strs OhioSeptember 20, 2025 | marketbeat.comDeclining Stock and Decent Financials: Is The Market Wrong About Vericel Corporation (NASDAQ:VCEL)?September 18, 2025 | finance.yahoo.comVericel downgraded to Neutral from Buy at BTIGSeptember 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRRO, VCEL, JANX, and EWTX Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$15.39 +0.33 (+2.19%) Closing price 04:00 PM EasternExtended Trading$15.20 -0.20 (-1.27%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Janux Therapeutics NASDAQ:JANX$26.91 +0.15 (+0.56%) Closing price 04:00 PM EasternExtended Trading$27.90 +0.99 (+3.68%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Korro Bio NASDAQ:KRRO$46.35 +4.20 (+9.96%) Closing price 04:00 PM EasternExtended Trading$44.34 -2.01 (-4.33%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Vericel NASDAQ:VCEL$36.02 +0.70 (+1.98%) Closing price 04:00 PM EasternExtended Trading$36.08 +0.06 (+0.17%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
